

West Virginia Medicaid Drug Utilization Review Board Minutes February 14, 2024

The West Virginia Medicaid Drug Utilization Review (DUR) Board meeting was called to order with the following in attendance:

Members:

Christopher Terpening, PharmD, PhD, Chair
Chris Booth, PharmD
Michael Ballow, PharmD
Scott Brown, RPh
Kate Forman, PharmD
Phillip Galapon, MD
Lester Labus, MD
Michael Lonsinger, PharmD
Ernest Miller, DO
Mary Nemeth-Pyles, MSN, RN, CS

Members Absent:

David Gloss, MD, Vice Chair
C.K. Babcock, PharmD

DoHS/BMS Staff:

Kristen Boustany, PharmD
Vicki Cunningham, PharmD, Director of Pharmacy
William Hopkins, PharmD, Pharmacy Operations Manager
Lori Moles, PharmD
Priya Shah, PharmD, Drug Utilization Review Coordinator
Doug Sorvig, Data Analyst

Contract Staff:

Joe Bergondo, PharmD – Change Healthcare
Jacquelyn Hedlund, MD – Change Healthcare
Eric Sears, RPh – Gainwell
Angie Wowczuk, PharmD – Rational Drug Therapy Program (RDTP)
Cory Chambliss – Acentra Health
Scott Donald, PharmD – Acentra Health
Alena Mitchell, PharmD – Acentra Health

1. INTRODUCTIONS

- a. Dr. Chris Terpening, Chair, welcomed everyone to the Board meeting at 4:03 PM (EST). The DUR Board and others introduced themselves.

2. APPROVAL OF MINUTES FROM November 15th, 2023, DUR BOARD MEETING

- a. A motion was made, seconded, and approved to accept the minutes from the previous DUR meeting with no further discussion.

3. **OLD BUSINESS**

- a. None

4. **NEW BUSINESS**

- a. **Speakers**

- i. None

- b. **Updates from January 24th, 2024, P&T Committee Meeting**

- i. Dr. Joe Bergondo presented the PDL status updates from the January 24th, 2024, P&T meeting.

- c. **Prior Authorization Criteria.** Attachment A

- i. **Hypoglycemia treatment:** announced that PA requirements removed for Zegalogue and Baqsimi due to glucagon shortage.
 - ii. **Likmez:** approved as presented.
 - iii. **Motpoly XR:** approved as presented.
 - iv. **Rykindo:** approved as presented.
 - v. **Xdemby:** approved as presented.

5. **REPORTS – 4th Quarter of 2023**

- a. **Gainwell Technologies Quarterly Report:** Mr. Eric Sears presented an overview of the 2023 Fourth Quarter Report which included a review of the DUR Quarterly Overall Summary Report. Attachment B.
- b. **Rational Drug Therapy Program:** Dr. Angela Wowczuk presented a summary of the prior authorization program for the Fourth Quarter of 2023. Attachment C.
- c. **Acentra Health:** Dr. Alena Mitchell presented a summary of the RDUR interventions for the Fourth Quarter of 2023. Attachment D.

6. **OTHER BUSINESS**

- a. None

7. **NEXT MEETING AND ADJOURNMENT**

- a. The meeting concluded at 4:55 PM (EST).
- b. The next meeting will be May 22nd, 2024, from 4-6 PM (EST) on a virtual platform.